ANDA 204343, held by Hetero Labs Ltd Iii. Duloxetine Hydrochloride.
As of Nov 16, 2026, ANDA 204343 (Duloxetine Hydrochloride), held by Hetero Labs Ltd Iii, was first approved by FDA on Aug 3, 2016, with 6 approved supplements and 0 published complete response letters.
Duloxetine delayed-release capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2016 | Original application | Approved | None posted |
| Duloxetine HydrochlorideEQ 20MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 30MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 60MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Feb 18, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Feb 18, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 30, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 30, 2020 | Supplement 4Manufacturing | Approved | None posted |
| Dec 30, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 19, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 3, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters